Savolitinib is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase, primarily developed for the treatment of non-small cell lung cancer (NSCLC) withMETmutations. It is also being investigated as a treatment for breast, head and neck, colorectal, gastric, pancreatic, and other gastrointestinal cancers. In both preclinical and clinical studies, it has demonstrated efficacy in lung, kidney, and stomach cancers. Savolitinib is an oral anti-cancer medication taken as a 600 mg dose once daily. It can be used as a monotherapy in patients with non-small cell lung cancer withMETmutations and in combination with epidermal growth factor receptor (EGFR) inhibitors for patients who have developed resistance to them. Furthermore, savolitinib has shown positive results in gastric cancer treatment, particularly in combination with docetaxel. As a result, this review aims to validate its efficacy in NSCLC and suggests its potential application in other gastrointestinal cancers, such as pancreatic cancer, based on related research in gastric and renal cancer.
Savolitinib是一种高选择性间质上皮转化因子（MET）酪氨酸激酶小分子抑制剂，主要针对MET突变的非小细胞肺癌（NSCLC）治疗而开发。该药物亦在乳腺癌、头颈部肿瘤、结直肠癌、胃癌、胰腺癌及其他胃肠道癌症的治疗研究中展现出潜力。临床前及临床研究数据表明，Savolitinib在肺癌、肾癌和胃癌中均显示出疗效。该药物为口服抗癌制剂，每日一次600mg给药方案。对于MET突变的非小细胞肺癌患者，可单药使用；对于表皮生长因子受体（EGFR）抑制剂产生耐药性的患者，则可与EGFR抑制剂联合用药。此外，Savolitinib在胃癌治疗中（特别是与多西他赛联用时）已取得积极成果。基于其在胃癌和肾癌中的相关研究，本综述旨在验证Savolitinib在非小细胞肺癌中的疗效，并探讨其在胰腺癌等其他胃肠道恶性肿瘤中的潜在应用价值。
肿瘤(癌症)患者之家